Three major variants (v1: E13;A20, v2: E20;A20, and v3: E6;A20) account for more than 90% of lung cancers patients with fusion of ALK and EML-4 (Echinoderm Microtubule-Associated Protein-Like 4) genes. This evidence concerns the gene EML4 and lung cancer.